资讯

Clinical Trials Arena on MSN21 小时
Boehringer’s HER2-mutated lung cancer drug shows sustained benefit for 14 months
Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...